---
title: Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks
date: '2024-05-31'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38819658/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20240531182133&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: Oral sebetralstat provided faster times to the beginning
  of symptom relief, reduction in attack severity, and complete attack resolution
  than placebo. (Funded by KalVista Pharmaceuticals; KONFIDENT ClinicalTrials.gov
  number, NCT05259917; EudraCT number, ...'
disable_comments: true
---
CONCLUSIONS: Oral sebetralstat provided faster times to the beginning of symptom relief, reduction in attack severity, and complete attack resolution than placebo. (Funded by KalVista Pharmaceuticals; KONFIDENT ClinicalTrials.gov number, NCT05259917; EudraCT number, ...